Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

NCT00448539 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT00448539
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00448539 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
Lead sponsor
Eisai Inc.
Phase
Phase 3
Overall status
Terminated
Start date
March 15, 2007
Completion date
May 14, 2010
Enrollment
286 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

refractory partial onset seizures